Fair Value Calculator Fair Value Calculator
EN DE

DEEPAKCHEM (DEEPAKCHEM) Fair Value & Analysis

IN · Market cap ₹869M

D DEEPAKCHEM DEEPAKCHEM · BSE
Price₹79.99
Fair Value₹115.34
Upside+44.2%
Quality35/100
Watch DEEPAKCHEM for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range ₹80.74 – ₹149.94

Fair value as of: Jul 5, 2026

From 12 valuation models · updated today

Share price −4.8% over the past month.

Price vs Fair Value (12 months)

₹169.10 ₹69.50 Fair Value ₹115.34 Jul 2025 Jul 2026

12‑month range ₹69.50 – ₹169.10 · fair‑value band ₹80.74 – ₹149.94 · the ₹79.99 price screens below the ₹115.34 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

DEEPAKCHEM (DEEPAKCHEM) currently trades at ₹79.99, while our model-based Fair Value estimate is ₹115.34 — implying the stock looks roughly 44.2% undervalued today. We read business quality at 35/100 (below-average quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, DEEPAKCHEM generated revenue of ₹676M at a net margin of 12.2%. Revenue declined 10.1% year over year. It earns a return on equity of 15.7%. Net debt stands at ₹3.6M. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹80.74 (bear case) to ₹149.94 (bull case); at ₹79.99, the current price sits below that range. The share trades about 53% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.

Key figures & financial health

Revenue (TTM) ₹676M
Revenue growth (YoY) -10.1%
Net margin 12.2%
Return on equity 15.7%
Free cash flow −₹58.8M FY2026
P/E ratio 10.3
More key figures
Operating margin 10.7%
EPS (TTM) ₹7.80
EPS growth (YoY) -38.4%
Net debt ₹3.6M FY2023

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

DEEPAKCHEM reported revenue of ₹676M in FY2026 versus ₹541M in FY2022, a compound +5.7%/yr. Reported net income was ₹82.5M in FY2026, compounding +18.2%/yr from FY2022.

Revenue +5.7%/yr
FY22 ₹541M
FY23 ₹467M
FY24 ₹494M
FY25 ₹794M
FY26 ₹676M
Net income +18.2%/yr
FY22 ₹42.3M
FY23 ₹61.2M
FY24 ₹59.7M
FY25 ₹124M
FY26 ₹82.5M

Is DEEPAKCHEM fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "DEEPAKCHEM Fair Value". https://www.fairvalue-calculator.com/stock/DEEPAKCHEM

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is DEEPAKCHEM (DEEPAKCHEM) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹115.34 versus a price of ₹79.99 — about +44% (undervalued). Model-based estimate, not financial advice.
What is the fair value of DEEPAKCHEM?
Our model-based fair value for DEEPAKCHEM is ₹115.34 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹79.99.
What is the quality score of DEEPAKCHEM?
DEEPAKCHEM has a Quality Score of 35/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of DEEPAKCHEM (DEEPAKCHEM)?
DEEPAKCHEM reported trailing-twelve-month revenue of about ₹676M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of DEEPAKCHEM?
The net profit margin of DEEPAKCHEM is about 12.2%, meaning it keeps roughly 12.2% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.